Lantheus Holdings Stock News

Lantheus LNTH +34%. Evolent Health (EVH) +18%. Orphazyme (ORPH) -36%. Rhythm Pharmaceuticals RYTM -24%.

Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 47.06% and 14.81%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Healthcare supplier Lantheus Holdings (LNTH) has added ~32% in the pre-market Thursday on above-average volume after the company set its outlook ahead of Wall Street forecasts on the…

Lantheus Holdings Inc (NASDAQ: LNTH ) reported Q4 sales of $129.6 million , +37.6% Y/Y, beating the consensus of $111.76 million. The company''s Q4 adjusted EPS reached $0.25, higher than $0.07 reported a year ago, better than the consensus of $0.17. Free Cash Flow was $9.3 million for Q4 of 2021 compared to $(3.2) million for Q4 of 2020. The gross margin improved to 44.7% from 41.1% a … Full story available on Benzinga.com

NEW YORK , Feb. 24, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INDO, SJI, LNTH, USWS, and TELL. … Full story available on Benzinga.com

Partnership leverages Palette''s specialty sales team to increase promotional footprint of PYLARIFY within the urology call point SANTA BARBARA, Calif. and STOCKHOLM, Sweden, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences ("Palette"), a global medical device company dedicated to improving prostate radiation therapy outcomes, announced the signing of an Agreement with Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH ) to support the promotion of PYLARIFY ® (piflufolastat F 18) in the United States. PYLARIFY injection is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and soft tissue metastases to determine the presence of recurrent and/or metastatic prostate cancer. PYLARIFY was approved by the U.S. Food and Drug Administration in May 2021. The Agreement provides for Palette''s specialty Urology and Radiation Oncology sales team to fortify Lantheus'' substantial promotional efforts and reach additional U.S. healthcare professionals.

Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 47.06% and 14.81%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Lantheus Holdings, Inc. (LNTH) CEO Mary Anne Heino on Q4 2021 Results - Earnings Call Transcript

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 18.42% and 10.81%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahea

Lantheus (NASDAQ:LNTH) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is $0.17 (+142.9% Y/Y) and the

Lantheus Holdings (LNTH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed thro

Lantheus Holdings (LNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Baxter (BAX) delivered earnings and revenue surprises of 0.97% and 4.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

NORTH BILLERICA, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imag